We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Low-Frequency TP53 Gene Mutations Also Found in Healthy Women

By LabMedica International staff writers
Posted on 19 Jul 2019
Worldwide, more than 250,000 new cases of ovarian cancer are diagnosed each year, and two-thirds of these women die from the disease. More...
This high mortality is largely due to the high frequency of metastasis before diagnosis and a lack of effective screening and early detection methods.

In recent years, it has been demonstrated that cancers can be non-invasively detected in “liquid biopsies,” that is, blood or other body fluids in which cancers shed cells or DNA high-accuracy next-generation DNA sequencing. This promises a paradigm shift in early cancer detection by enabling the identification of mutant cancer molecules in minimally invasive body fluid samples.

Scientists at the University of Washington (Seattle, WA, USA) and their colleagues combined trans-cervical lavage of the uterine cavity with duplex sequencing, an approach they argued would boost collection efficiency and their ability to detect mutations. Under blinded conditions, they analyzed samples from 10 women with ovarian cancer and 11 controls, and correctly identified ovarian cancer in eight of the 10 cases. But they noticed low-frequency background TP53 mutations within lavages from all the women, even those who did not have cancer, a finding they confirmed by droplet digital polymerase chain reaction.

The TP53 mutations they found in samples from cancer-free women were not spread randomly across the gene. Instead, they reported that about a quarter of them occurred in a CpG dinucleotide context, even though those dinucleotides make up less that 5% of the TP53 coding region, and that mutations were enriched for in the exons that encode the protein's DNA-binding domain. This, they said, indicates the mutations are under positive selection. Further, these background TP53 mutations strongly resembled ones logged in cancer databases. Mutations from both groups, they added, were largely missense mutations and enriched in G to A and C to T transitions.

They expanded their cohort to include tissue samples from a neonate who died of a congenital vascular malformation and 101-year-old woman who died of natural causes. TP53 mutations were more frequent in three different tissues tested in the centenarian than in the neonate. Rosa- Ana Risques, PhD, an Assistant Professor of Pathology and senior author of the study, said, “The implications of our findings are important as a cautionary message for mutation-based cancer biomarkers. At the same time as we have shown that highly sensitive [next-generation sequencing] methods are essential for maximal mutation detection, we have also illustrated a substantial specificity challenge related to biology, not technology, the extent of which has been underappreciated.” The study was published on July 2, 2019, in the journal Cell Reports.

Related Links:
University of Washington


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Pipette Management Software
VIALINK
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.